List of Jesduvroq drug patents
Jesduvroq is owned by Glaxosmithkline.
Jesduvroq contains Daprodustat.
Jesduvroq has a total of 4 drug patents out of which 0 drug patents have expired.
Jesduvroq was authorised for market use on 01 February, 2023.
Jesduvroq is available in tablet;oral dosage forms.
Jesduvroq can be used as treatment of anemia due to chronic kidney disease, a method of treating anemia.
Drug patent challenges can be filed against Jesduvroq from 2027-02-01.
The generics of Jesduvroq are possible to be released after 13 March, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(5 years from now) | |
| US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(4 years from now) | |
| US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 1, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 2027-02-01
Market Authorisation Date: 01 February, 2023
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic